A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.

Wai Meng David Tai,Kelvin S. H. Loke,Apoorva Gogna,Sze Huey Tan,David Chee Eng Ng,Tiffany Hennedige,Farah Gillan Irani,Joycelyn Jie Xin Lee,Chow Wei Too,Matthew C.H. Ng,Chee Kian Tham,Justina Yick Ching Lam,Si-Lin Koo,Alexander Y. F. Chung,Han Chong Toh,Choon Hua Thng,Kiat Hon Lim,Joe Poh Sheng Yeong,Chung-Yip Chan,Su Pin Choo

A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.

2020

4590Background: Nivolumab (N) and Y90-radioembolization (RE) are both therapeutic options in advanced hepatocellular carcinoma (aHCC). Increasing evidence suggests that radiotherapy synergizes with...

Keywords:

Internal medicine
Single Center
Oncology
Nivolumab
Hepatocellular carcinoma
Pathology
open label
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations